Heart researcher who faked patient data gets 4th retraction

XLargeThumb.00004872-201512000-00000.CVA heart researcher who fabricated patient records for her studies on the blood pressure medication ramipril has earned her fourth retraction, and more are apparently on the way.

For readers who are new to this case: Things first unraveled for Anna Ahimastos when a subanalysis of a JAMA clinical trial revealed “anomalies,” triggering an investigation. After Ahimastos admitted to fabricating patient data, that JAMA paper and two others — including a small trial in Annals of Internal Medicine — were pulled. A spokesperson for her former employer, Baker IDI Heart & Diabetes Institute, told us last week that they have requested more retractions:

Five papers and one letter are in the process of being retracted.

The Annals and this latest paper are included in the five papers, so we expect to see Continue reading Heart researcher who faked patient data gets 4th retraction

Surgery journal publishes — then retracts — response to letter that never appeared

Annals of Surgery

How’s this for confusing: A surgery journal is retracting researchers’ response to a letter about their paper, because the letter was never actually published.

According to the managing editor of the Annals of Surgery, the letter — about a 2011 analysis of IV fluids in trauma patients — was accepted, prompting the journal to ask for a response from the authors of the 2011 paper. But the letter-writers never supplied required forms, such as conflict of interest. After spending two years trying to track them down, the journal decided not to publish the letter.

In the meantime, however, the authors’ response to the letter was “inadvertently published,” forcing the journal to retract it. Continue reading Surgery journal publishes — then retracts — response to letter that never appeared

Boldt’s retraction count upped to 94, co-author takes legal action to prevent 95th

Screen Shot 2015-09-16 at 12.12.13 AM

We’ve found two recent retractions and an expression of concern for Joachim Boldt, former prominent anesthesiologist and currently Retraction Watch leaderboard’s 2nd place titleholder. He now has 94 retractions.

One of the retracted articles contains falsified data, along with a researcher who didn’t agree to be a co-author, according to an investigation by the Justus Liebig University Giessen, where Boldt used to work. The expression of concern is regarding some questionable data. The other new retraction is actually one of 88 papers that a group of editors agreed to retract back in 2011, after they were “unable to verify” approval by the Institutional Review Board (IRB) for the studies.

One of those 88 papers, we’ve discovered, has still has not been retracted. According to an editor at the journal, they haven’t removed it because one of Boldt’s co-authors has threatened them with legal action. Continue reading Boldt’s retraction count upped to 94, co-author takes legal action to prevent 95th

How long does it take to retract a paper? A look at the Eric Poehlman record

oriweb_logoIn 2005, the U.S. Office of Research Integrity announced that obesity researcher Eric Poehlman had committed misconduct in 10 published papers. You might think that all of those ten articles would have been retracted a decade later.

You’d be wrong. Only six of them have. Here’s what Elizabeth Wager (a member of the board of directors of The Center For Scientific Integrity, our parent non-profit organization) found when she went looking through the record. Continue reading How long does it take to retract a paper? A look at the Eric Poehlman record

Gut paper retracted after university review says “figures cannot be validated by original data”

IBDA biologist at Case Western Reserve University School of Medicine in Ohio has retracted a paper from Inflammatory Bowel Diseases after a university review found the figures within it could not be “validated by original data.”

The 2010 paper, “Elevated IL-13Rα2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway,” concerns the elevated expression and role of an inflammatory protein in colon cancer cells.

According to the notice, corresponding author and biologist Alan Levine — who recently received a $3.9 million Avant-Garde Award for HIV/AIDS Research from the National Institute on Drug Abuse — requested the retraction.

Here’s the full notice: Continue reading Gut paper retracted after university review says “figures cannot be validated by original data”

Cervical cancer paper is scrapped for duplication in the same journal, year

XLargeThumb.00009577-201507000-00000.CVOver a decade ago, a case report on a woman with cervical cancer and lymphoma was “published twice” by the International Journal of Gynecological Cancer within the span of a few months. The retraction note came out just now.

One copy of the paper appeared in the July 2003 issue of the journal. The second, now-retracted, copy — “Coincidental detection of T-cell rich B cell lymphoma in the para-aortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer: A case report” — was published later that year, in the September issue.

There are just a few cosmetic differences between the headlines and abstracts of the papers  — a “;” instead of a “,”; a change in verb tense, and a typo, for instance. (See a text comparison of the abstracts here.)

The brief retraction note, from the journal’s Editor in Chief Uziel Beller, doesn’t explain what took so long to act on the error — just tosses the blame to whoever was in charge of the journal at the time:

Continue reading Cervical cancer paper is scrapped for duplication in the same journal, year

“Serious and obvious mistakes” kill paper on heart attacks in rats

j card pharmA group of researchers in China and the United States have retracted a 2014 paper in the Journal of Cardiovascular Pharmacology after discovering the data were fatally flawed.

The article examined whether the anti-arrhythmia drug zacopride affected cardiac remodeling after heart attack, and came from Bo-We Wu, of Shanxi Medical University, in Taiyuan, and colleagues, including one author from Savannah, Georgia.

Here’s more from the notice for “Activation of IK1 channel by zacopride attenuates left ventricular remodeling in rats with myocardial infarction”:

Continue reading “Serious and obvious mistakes” kill paper on heart attacks in rats

Pain paper scratched for authorship issues

ejacoverA group of pain researchers in Austria has lost their 2014 paper in the European Journal of Anaesthesiology because one of the authors wasn’t, well, one of the authors.

The article, “Intravenous nonopioid analgesic drugs in chronic low back pain patients on chronic opioid treatment: A crossover, randomised, double-blinded, placebo-controlled study,” came from a team at the Medical University Vienna and Evangelical Hospital Vienna.

During the study, the authors tested whether intravenous infusions of nonopioid drugs (such as paracetamol, or Tylenol) helped people with chronic back pain who take opioids regularly. They found that people’s pain levels decreased in the days leading up to treatment, when they were receiving a placebo, but not after the actual infusion. The results likely stem from “expectation-related mechanisms,” they wrote. Continue reading Pain paper scratched for authorship issues

Heart study bleeds into three papers, one retracted and one withdrawn

janWith the increasingly hectic pace of modern life, everybody is always on the look out for time-saving tricks and tips.

Scientists at the National University of Singapore and the Hong Kong Polytechnic University certainly found one, but we really can’t recommend it: doing one randomized controlled trial (RCT) with several outcomes, and publishing them as three separate 2014 papers with “considerable overlap.”

So far, one paper has been retracted, and another withdrawn.

Continue reading Heart study bleeds into three papers, one retracted and one withdrawn

Fake peer review fells two more papers

medicineThe number of papers retracted for fake peer reviews — well in excess of 100, by our count — continues to grow.

The latest to join the list are “Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in treatment of endoscopic submucosal dissection-induced gastric ulcer: a meta-analysis of randomized controlled trials” and “Association study of TGFBR2 and miR-518 gene polymorphisms with age at natural menopause, premature ovarian failure and early menopause among Chinese Han women,” both published in 2014 in Medicine.

Here’s how both notices, signed by senior publisher Duncan A. MacRae, read: Continue reading Fake peer review fells two more papers